USANA Health Sciences (NYSE:USNA) Releases Q3 2021 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its third quarter 2021 earnings guidance on Thursday. The company provided EPS guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.

Shares of USNA stock traded up $0.21 during trading hours on Thursday, reaching $97.39. The company’s stock had a trading volume of 100 shares, compared to its average volume of 88,851. USANA Health Sciences has a fifty-two week low of $73.00 and a fifty-two week high of $107.85. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 14.66 and a beta of 0.85. The firm’s 50 day simple moving average is $94.42 and its 200-day simple moving average is $98.19.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 27th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.78 by $0.09. USANA Health Sciences had a net margin of 11.09% and a return on equity of 33.65%. The business had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $340.20 million. On average, research analysts expect that USANA Health Sciences will post 6.31 EPS for the current year.

A number of equities analysts recently weighed in on USNA shares. Tigress Financial reissued a buy rating and set a $122.00 target price on shares of USANA Health Sciences in a research note on Friday, October 8th. Zacks Investment Research upgraded USANA Health Sciences from a sell rating to a hold rating in a research report on Wednesday, September 29th.

In other news, Director John Turman Fleming sold 300 shares of the stock in a transaction that occurred on Monday, August 30th. The shares were sold at an average price of $97.26, for a total transaction of $29,178.00. Following the completion of the transaction, the director now directly owns 851 shares of the company’s stock, valued at approximately $82,768.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frederic J. Winssinger sold 926 shares of the stock in a transaction on Thursday, July 29th. The shares were sold at an average price of $99.08, for a total value of $91,748.08. Following the transaction, the director now directly owns 2,516 shares of the company’s stock, valued at $249,285.28. The disclosure for this sale can be found here. Insiders have sold a total of 3,435 shares of company stock valued at $331,837 in the last 90 days. 0.21% of the stock is currently owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

See Also: What moving averages are used to define a golden cross?

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with's FREE daily email newsletter.